The development of a “10-minute cancer test”: the Methylscape

By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …

Does lowering lipid levels really affect risk for prostate cancer and prostate cancer-specific mortality?

As our regular readers will be well aware, there have been a number of published papers suggesting associations between the use of statins and other lipid-lowering agents and risk for diagnosis with and progression of prostate cancer over time. … READ MORE …

PCaI joins with Cancer ABCs to advocate for protection of access to cancer and other drugs

For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …

Can RP + EBRT + ADT provide equal outcomes to brachy boost therapy + ADT in high-risk men?

As we have seen previously (see this link), among men with Gleason 9 or 10 disease, brachy boost therapy (BBT) provided better oncological outcomes compared to either radical prostatectomy (RP) alone or external beam radiation therapy (EBRT) alone. … READ MORE …

Is Problem X really a side effect of ADT, or not …?

We have long been bedeviled by questions about some of the short- and the long-term side effects and complications of androgen deprivation therapy (ADT) in the treatment of prostate cancer. … READ MORE …

How accurate are gallium-68 PSMA PET/CT scans in the “real world”?

A new article in the journal Cancer Imaging has provided us with an interesting set of “real world” data on the accuracy of gallium-68 PSMA PET/CT scans in the management of prostate cancer. … READ MORE …

First-line treatment for prostate cancer and use of antidepressants

According to a recently reported study in the journal European Urology, men who received first-line surgery or radiation therapy for non-metastatic prostate cancer were significantly more likely to have taken an antidepressant 5 years later than comparable men who didn’t get such treatment. … READ MORE …